191 related articles for article (PubMed ID: 7809953)
41. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence.
Bubar MJ; Cunningham KA
Curr Top Med Chem; 2006; 6(18):1971-85. PubMed ID: 17017968
[TBL] [Abstract][Full Text] [Related]
42. Being partial to psychostimulant addiction therapy.
Pulvirenti L; Koob GF
Trends Pharmacol Sci; 2002 Apr; 23(4):151-3. PubMed ID: 11931978
[No Abstract] [Full Text] [Related]
43. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.
Brown ES; Jeffress J; Liggin JD; Garza M; Beard L
J Clin Psychiatry; 2005 Jun; 66(6):756-60. PubMed ID: 15960570
[TBL] [Abstract][Full Text] [Related]
44. Pharmacotherapy of cocaine abuse: preclinical development.
Witkin JM
Neurosci Biobehav Rev; 1994; 18(1):121-42. PubMed ID: 8170620
[TBL] [Abstract][Full Text] [Related]
45. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat.
Pulvirenti L; Balducci C; Piercy M; Koob GF
J Pharmacol Exp Ther; 1998 Sep; 286(3):1231-8. PubMed ID: 9732383
[TBL] [Abstract][Full Text] [Related]
46. [Principles of the pharmacological treatment of drug addiction].
Saadan M; Scuvée-Moreau J; Seutin V
Rev Med Liege; 2013; 68(5-6):245-51. PubMed ID: 23888572
[TBL] [Abstract][Full Text] [Related]
47. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development.
Platt DM; Rowlett JK; Spealman RD
Psychopharmacology (Berl); 2002 Oct; 163(3-4):265-82. PubMed ID: 12373428
[TBL] [Abstract][Full Text] [Related]
48. Effects of a partial dopamine D2-like agonist on the cocaine-induced behavioral sensitization of preweanling rats.
Sibole JM; Matea PJ; Krall CM; McDougall SA
Pharmacol Biochem Behav; 2003 Aug; 76(1):27-34. PubMed ID: 13679214
[TBL] [Abstract][Full Text] [Related]
49. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Keck TM; John WS; Czoty PW; Nader MA; Newman AH
J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
[TBL] [Abstract][Full Text] [Related]
50. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
[No Abstract] [Full Text] [Related]
51. Animal models of addiction: models for therapeutic strategies?
Wolffgramm J; Galli G; Thimm F; Heyne A
J Neural Transm (Vienna); 2000; 107(6):649-68. PubMed ID: 10943906
[TBL] [Abstract][Full Text] [Related]
52. The place of partial agonism in psychiatry: recent developments.
Ohlsen RI; Pilowsky LS
J Psychopharmacol; 2005 Jul; 19(4):408-13. PubMed ID: 15982997
[TBL] [Abstract][Full Text] [Related]
53. A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction.
Gardner EL; Liu X; Paredes W; Giordano A; Spector J; Lepore M; Wu KM; Froimowitz M
Neuropharmacology; 2006 Oct; 51(5):993-1003. PubMed ID: 16901516
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological adjuncts in the treatment of opioid and cocaine addicts.
Herridge P; Gold MS
J Psychoactive Drugs; 1988; 20(3):233-42. PubMed ID: 3069983
[TBL] [Abstract][Full Text] [Related]
55. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.
Bubar MJ; Cunningham KA
Prog Brain Res; 2008; 172():319-46. PubMed ID: 18772040
[TBL] [Abstract][Full Text] [Related]
56. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors.
Weiss F; Ciccocioppo R; Parsons LH; Katner S; Liu X; Zorrilla EP; Valdez GR; Ben-Shahar O; Angeletti S; Richter RR
Ann N Y Acad Sci; 2001 Jun; 937():1-26. PubMed ID: 11458532
[TBL] [Abstract][Full Text] [Related]
57. Effects of Acute and Chronic Treatments with Dopamine D
Thomsen M; Barrett AC; Butler P; Negus SS; Caine SB
J Pharmacol Exp Ther; 2017 Jul; 362(1):161-176. PubMed ID: 28473458
[TBL] [Abstract][Full Text] [Related]
58. [Use of dopamine agonists in the treatment of Parkinson's disease].
Gekht AB
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
[No Abstract] [Full Text] [Related]
59. Bromocriptine in cocaine withdrawal--does it work?
Teller DW; Devenyi P
Int J Addict; 1988 Nov; 23(11):1197-205. PubMed ID: 3069753
[TBL] [Abstract][Full Text] [Related]
60. Pharmacotherapy for opioid and cocaine abuse.
Warner EA; Kosten TR; O'Connor PG
Med Clin North Am; 1997 Jul; 81(4):909-25. PubMed ID: 9222260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
